期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Integrated combination delivery of IDO inhibitor and paclitaxel for cancer treatment 被引量:1
1
作者 Dakuan Wang Bo Peng +9 位作者 Mengmeng Qin Minghui Li Ge Song Bing He Hua Zhang Wenbing Dai Qiang Zhang Xiangbao Meng Huan Meng Xueqing Wang 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2021年第1期1-16,共16页
In order to realize the combination of chemotherapy and immunotherapy,a reduction-responsive paclitaxel(PTX)prodrug PEG-SS-PTX was synthesized and used as a carrier to encapsulate IDO inhibitor CY-1-4 for preparing PE... In order to realize the combination of chemotherapy and immunotherapy,a reduction-responsive paclitaxel(PTX)prodrug PEG-SS-PTX was synthesized and used as a carrier to encapsulate IDO inhibitor CY-1-4 for preparing PEG-SS-PTX/CY-1-4 NPs.PEG-SS-PTX/CY-1-4 NPs were evaluated by cytotoxicity,immunogenic cell death(ICD)induction ability and anti-tumor efficacy.Dynamic light scattering(DLS)results showed that the size of PEG-SS-PTX/CY-1-4 NPs was about 149 nm.In vitro experiments indicated that its cytotoxicity was in a concentration-dependent manner,and it induced the ICD of B16-F10 cells.In vivo studies in melanoma mouse model indicated that PEG-SS-PTX/CY-1-4 NPs significantly inhibited the tumor growth and reduced the expression of IDO in tumor tissues.Moreover,it increased the rate of CD8+T cells in the spleen.In summary,PEG-SS-PTX/CY-1-4 NPs achieved good anti-tumor effects and reduced the dose of chemotherapy drugs,which was a safe and effective combined delivery system. 展开更多
关键词 CHEMOTHERAPY IMMUNOTHERAPY Combination drug delivery Nano drug delivery system IDO activity inhibition Immunogenic cell death
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部